Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Strand's India Laboratory Receives CAP, NABL Accreditations

This article has been corrected to reflect that Strand Life Sciences' original claim that its lab was the first in India to recieve both CAP and NABL accreditations was incorrect. 

NEW YORK (GenomeWeb) – Strand Life Sciences announced today that the Strand Center for Genomics and Personalized Medicine — the company's next-generation laboratory based in Bangalore, India — has received accreditation certificates from both the College of American Pathologists (CAP), and the National Accreditation Board for Testing & Calibration Laboratories (NABL).

The Strand Center lab recent accreditation shows the high quality at which it operates, the company said. The CAP laboratory accreditation program is recognized by the US federal government as equal-to or more stringent than the government's own laboratory inspection programs. The accreditation by NABL, the sole government-authorized laboratory accreditation body in India, is in accordance with ISO 15189:2012 standards.

"The accreditation of our India facility by CAP and NABL (ISO 15189) validates our ability to perform high quality clinical NGS testing and perform bioinformatics and clinical interpretation to international quality standards in every facility that we operate," Strand's Global Head of Diagnostics Preveen Ramamoorthy said in a statement.

The lab is now accredited to provide three of the company's most popular tests: the StrandAdvantage 48-gene test, which is used to profile cancer patients for somatic mutations and personalize treatment; the Strand Germline Cancer test, an 86 gene hereditary cancer test that estimates inherited cancer risk; and the Strand Rare Diseases test, which covers more than 500 genes and 400 rare inherited diseases used for confirmation of diagnosis and carrier testing in couples.

Other laboratories with both CAP and NABL accreditaions in India include SRL Diagnostics Laboratories, VIMTA, Pathcare Labs, and Reliance Life Sciences. 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.